GEM Stock Overview
A clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
GeNeuro SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.081 |
| 52 Week High | €2.42 |
| 52 Week Low | €0.027 |
| Beta | 0.48 |
| 1 Month Change | -40.51% |
| 3 Month Change | 165.36% |
| 1 Year Change | -92.00% |
| 3 Year Change | -97.43% |
| 5 Year Change | -96.88% |
| Change since IPO | -99.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| GEM | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -22.3% | -3.7% | 3.3% |
| 1Y | -92.0% | -17.9% | 18.1% |
Return vs Industry: GEM underperformed the German Biotechs industry which returned -15.8% over the past year.
Return vs Market: GEM underperformed the German Market which returned 17.1% over the past year.
Price Volatility
| GEM volatility | |
|---|---|
| GEM Average Weekly Movement | 173.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: GEM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: GEM's weekly volatility has increased from 101% to 174% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 17 | Jesus Martin-Garcia | www.geneuro.com |
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development program.
GeNeuro SA Fundamentals Summary
| GEM fundamental statistics | |
|---|---|
| Market cap | €2.80m |
| Earnings (TTM) | -€14.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs GEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GEM income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €14.76m |
| Earnings | -€14.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -93.4% |
How did GEM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/06 19:21 |
| End of Day Share Price | 2025/03/06 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GeNeuro SA is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Le Berrigaud | Bryan Garnier & Co |
| Stephanie Lefebvre | Gilbert Dupont |
| Delphine Le Louet | Societe Generale Cross Asset Research |